Thumbnail Image
Publication

Drug Pricing Investigation: Amgen--Enbrel and Sensipar

House Committee on Oversight and Reform
Abstract
The House Committee on Oversight and Reform investigated Amgen, Inc.'s pricing practices for Enbrel and Sensipar from 2009 onward, revealing a pattern of uninhibited price hikes. Internal communications disclosed that pricing decisions were predominantly motivated by the imperative to meet aggressive revenue targets, exemplified by Sensipar's 8% price increase in 2017 and Enbrel's 9.7% hike in 2018. The Committee states that without significant structural reforms like Medicare negotiation, the pharmaceutical industry will continue to raise prices on critical and life saving medications, and many Americans will remain unable to afford their prescriptions.
Date
2020-10-01
Document Type
House Staff Report
Serial Number
Document Length
41 pages
Congress
116
Show all metadata
Files
Thumbnail Image
2020-10-01_R-Drug_Pricing_Investigation-(Amgen-Enbrel+Sensipar)-116C.pdf
Adobe PDF, 929.61 KB
Thumbnail Image
2020-10-01_R-Amgen-Enbrel+Sensipar-(selected_docs)-116C.pdf
Adobe PDF, 7.9 MB
URI
https://hdl.handle.net/20.500.14300/1170
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
Collections
House Oversight Committee